April 14, 2020—The American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Rhythm Society (HRS) jointly developed this new guidance to detail critical cardiovascular considerations in the use of hydroxychloroquine and azithromycin for the treatment of COVID-19. The statement also includes a table rating potential adverse cardiac events of medications repurposed for COVID-19 treatment, such as chloroquine and lopinavir/ritonavir (antimalarial and antiviral agents, respectively).
Recommended Resources: HRS COVID-19 Challenges & Solutions
Related Resources
Clinical Guidelines
18F-FDG PET/CT and Radiolabeled Leukocyte SPECT/CT Imaging for the Evaluation of Cardiovascular Infection in the Multimodality Context
The American Society of Nuclear Cardiology (ASNC) and Heart Rhythm Society (HRS), in partnership with 9 other societies, have released a consensus statement on the…
March 11, 2024
Clinical Guidelines
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation
The American College of Cardiology (ACC) and American Heart Association (AHA) released updated recommendations for preventing and managing atrial fibrillation. The new guideline was developed…
November 30, 2023
Clinical Guidelines
2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure
The Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Latin American Heart Rhythm Society (LAHRS) have partnered to provide guidance on cardiac…
May 20, 2023